Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dendritic Cells Pulsed with HIV antigens
- Development stage
- Phase 1
- Lead developer
- National Institute of Allergy and Infectious Diseases
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous, Intradermal
01
Overview
This investigational autologous dendritic cell-based therapeutic vaccine is developed by the National Institute of Allergy and Infectious Diseases (NIAID) for the treatment of HIV infection. The vaccine is produced by harvesting a patient's own dendritic cells and pulsing them ex vivo with specific HIV peptide antigens. Once re-administered, these mature dendritic cells function as potent antigen-presenting cells (APCs), aiming to prime and expand HIV-specific CD4+ and CD8+ T-lymphocyte populations. The goal of this immunotherapy is to enhance the host's immune control over viral replication, potentially allowing for sustained viral suppression during an analytical treatment interruption (ATI) from antiretroviral therapy.
- Other names
- Autologous HIV peptide-pulsed dendritic cell vaccineDendritic cell vaccine in HIV-infected individualsHIV peptide-pulsed dendritic cell vaccine
02
Targets
CD8A (CD8 alpha/beta Coreceptor)CD4 (T lymphocyte surface antigen)HIV-TCR (HIV-specific T-cell receptor)
Beyond the preview
Go deeper on Dendritic Cells Pulsed with HIV antigens.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dendritic Cells Pulsed with HIV antigens.